Comparison of prognoses according to non‐positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study. (19th March 2016)

• Record Type: Journal Article
• Authors: Maeda, Osamu; Miyata‐Takata, Tomoko; Shibata, Kiyosumi; Kajiyama, Hiroaki; Mizuno, Mika; Tamakoshi, Koji; Shimoyama, Yoshie; Nakamura, Shigeo; Kikkawa, Fumitaka
• Is Part Of: Cancer medicine. Volume 5:Number 6(2016:Jun.)
• Page Start: 1081
• Page End: 1092
• Publication Date: 2016-03-19
• Subjects: Anticancer drug resistance -- biomarker -- immunohistochemistry -- ovarian carcinoma -- prognosis -- spectrin αII; 616.994005
• DOI: 10.1002/cam4.683
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Anticancer drug sensitivity affects prognosis in ovarian carcinoma. Previously, we purified spectrin α II and β II tetramers from cisplatin‐resistant ovarian serous adenocarcinoma cells and demonstrated that they contribute to platinum anticancer drug resistance. In this clinical study, we focused on the role of spectrin α II expression. It is our objective to demonstrate the potential of spectrin α II expression as a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma. Spectrin α II expression in the ovarian adenocarcinoma surgical specimens of 193 patients was examined by immunohistochemical staining. Staining strength was scored 3+, regarded as positive expression, and 2+, 1+, and 0, regarded as non‐positive expression. Prognoses obtained from clinical records were evaluated by statistical analysis. In the 193 cases studied, positive spectrin α II expression was associated with worse overall survival when compared with non‐positive expression ( P < 0.001 by log‐rank test), and spectrin α II expression was identified as an independent predictive factor of overall survival (hazard ratio[HR]: 3.77, 95% confidence interval[CI]: 1.77–8.00; P < 0.001 by multivariate Cox's proportional hazards model). In the study about progression‐free survival, spectrin α II expression was not associated with prognoses. However, similar results as overall survival were obtained for survival after recurrence of the 92 recurrent cases ( P = 0.0051 by log‐rank test, HR: 4.49, 95% CI: 2.06–9.79; P < 0.001 by multivariate Cox's proportional hazards model). In a detailed overall survival study of 66 serous adenocarcinoma patients and 127 nonserous adenocarcinoma patients, similar results were also obtained. Spectrin α II expression is a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma.. Abstract : Spectrin α II expression in ovarian carcinoma surgical specimens can be scored according to the scoring criteria used in human epidermal growth factor receptor 2(HER2). Spectrin α II expression is an independent prognostic factor of overall survival and survival after recurrence in ovarian carcinoma. Spectrin α II expression is a useful predictor of anticancer drug resistance in ovarian carcinoma.